0001209191-23-044094.txt : 20230802 0001209191-23-044094.hdr.sgml : 20230802 20230802081736 ACCESSION NUMBER: 0001209191-23-044094 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230801 FILED AS OF DATE: 20230802 DATE AS OF CHANGE: 20230802 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lukowiak Andrew A CENTRAL INDEX KEY: 0001988083 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40047 FILM NUMBER: 231133812 MAIL ADDRESS: STREET 1: 1639 WINDEMERE DRIVE CITY: SAN MARCOS STATE: CA ZIP: 92078 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Talis Biomedical Corp CENTRAL INDEX KEY: 0001584751 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1100 ISLAND DRIVE STREET 2: SUITE 101 CITY: REDWOOD CITY STATE: CA ZIP: 94065 BUSINESS PHONE: 650-433-3000 MAIL ADDRESS: STREET 1: 1100 ISLAND DRIVE STREET 2: SUITE 101 CITY: REDWOOD CITY STATE: CA ZIP: 94065 FORMER COMPANY: FORMER CONFORMED NAME: SlipChip Corp DATE OF NAME CHANGE: 20130820 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-08-01 1 0001584751 Talis Biomedical Corp TLIS 0001988083 Lukowiak Andrew A C/O TALIS BIOMEDICAL CORP 1100 ISLAND DRIVE SUITE 101 REDWOOD CITY CA 94065 0 1 0 1 President Chief Scientific Officer /s/ Rebecca Markovich, Attorney-in-fact for Andrew A. Lukowiak 2023-08-02 EX-24 2 poa.txt POA DOCUMENT POWER OF ATTORNEY Know all by these presents, that the undersigned hereby constitutes and appoints each of REBECCA L. MARKOVICH and GILLIAN GREEN, signing individually, the undersigned's true and lawful attorneys-in-fact and agents to: (1) prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the United States Securities and Exchange Commission (the "SEC") a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or any rule or regulation of the SEC; (2) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of TALIS BIOMEDICAL CORPORATION (the "Company"), Forms 3, 4 and 5 (including any amendments thereto) in accordance with Section 16(a) of the Exchange Act and the rules thereunder; 2) do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to execute such Forms 3, 4 or 5 or Form ID (including any amendments thereto) and timely file such forms with the SEC and any stock exchange or similar authority; and (3) take any other action of any nature whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as such attorney-in-fact may approve in such attorney-in-fact's discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of July 26, 2023. /s/ Andrew A. Lukowiak